Circulating Tumor Cell (CTC) Market Share, Growth and Trends Analysis By Application (Research, Drug Development), Technology (CTC Enrichment, CTC Detection), End-User (Hospital & Clinics, Research & Academic Institutes, Diagnostic Centers) – Global Forecast Till 2023
Global Circulating Tumour Cells Market – Overview
The Cell search in Circulating Tumour Cell (CTC) Market test is a uncertain blood test that supports oncologists in assessing the diagnosis of patients with metastatic breast, prostate or colorectal cancer. The Cell search test is the only FDA approved test for Circulating Tumour Cells (CTC) valuation. Each result of the Cell search test executed are tested by both a cytotechnologist and a pathologist to authenticate the quality. Adding to this, pathologists and scientists are always accessible for consultation. These tests are majorly used for Circulating Tumour Cells (CTC) for Breast Cancer by Cell Search, Circulating Tumour Cells (CTC) for Colorectal Cancer by Cell Search, Circulating Tumour Cells (CTC) for Prostate Cancer by Cell Search.
Get Sample Report at https://www.marketresearchfuture.com/sample_request/1362
Further recent developments in healthcare technology now permit vigorous and reproducible exposure of circulating tumour cells (CTCs) from a simple blood test. Standardization in methodology have been influential in assisting multicentre trials with the purpose of evaluating the clinical utility of circulating tumour cells CTCs. Studying the current body of proof supporting the prognostic value of circulating tumour cells CTC enumeration in breast, prostate and colorectal cancer, using consistent approaches, and studies assessing the correlation of circulating tumour cells CTC number with radiological outcome. The exploitation of circulating tumour cells (CTCs) in cancer management, nevertheless, it is now extending beyond prognostication. As technologies develop to illustrate circulating tumour cells CTCs at the molecular level, biological information can be obtained in real time, with the promise of serving as a ‘surrogate tumour biopsy. Current studies by healthcare specialists lighten the potential of circulating tumour cells CTCs as pharmacodynamic and predictive biomarkers and possibly their use in revealing drug resistance in real time. Methodologies for circulating tumour cells CTC classification are summarized and the potential of circulating tumour cells CTCs in cancer patient management illustrated via the revealing of epidermal growth factor receptor mutations from circulating tumour cells CTCs in patients with non-small cell lung cancer. The prospect to learn more about the biology of metastasis with the help of circulating tumour cells CTC analysis is now being recognized with the horizon of circulating tumour cells CTC-guided development of novel anticancer therapies.
Key players in this market for Circulating Tumour Cells Market are ApoCell, Inc. (US), Biocep Ltd. (Israel), Fluxion Biosciences, Inc. (US), Biocept, Inc. (US), Biofluidica Microtechnologies LLC (US), Creatv Microtech, Inc. (US), Celltraffix Inc. (US), Clearbridge Biomedics (Singapore), Janssen Diagnostics LLC (US), Cynvenio Biosystems, Inc. (US), STEMCELL Technologies, Inc. (Canada), Epic Biosciences Inc. (US), Ikonisys, Inc. (US), IVDiagnostics, Inc. (US), ScreenCell (France), RARECELLS SAS (Italy), Epic Sciences (US), QIAGEN Hannover GmbH (Germany), Celula (US), Advanced Cell Diagnostics (US) and AdnaGen (Germany)
In the News
In November 2017: Epic Sciences, Inc. announces the release of its breast cancer single-cell profiling panel. This epics breast cancer panel is the most complete breast cancer biomarker panel available for classification of circulating tumour cells (CTCs) within a blood sample. Moreover, multiple biopharma and academic institutes are vigorously utilizing the panel as a clinical research tool to analyse the influence of dozens of novel and standard of care therapies in context to biochemical drivers of disease progression.
Furthermore, in addition to measuring modifications in CTC’s circulating tumour burden, the panel examines clinically relevant hormone receptor status, genomic drivers, and novel morphologic signatures for homologous recombination deficiency (HRD) and heterogeneity on every circulating tumour cells (CTC) individually. These biomarkers cover an enormous percentage of therapeutic classes presently working on clinical trials. The panel design permits flexibility of analysis based upon the needs of the clinical research being employed.
Further in November 2017 Clearbridge BioMedics and Leica Biosystems had an partnership to Co-market Automated Solutions for Circulating Tumor Cell (CTC) Analysis. This is precisely for the Clearbridge BioMedics ClearCell FX CTC enrichment system and the Leica Biosystems BOND RX staining platform. This new partnership provides an incorporated and mechanised workflow for circulating tumour cells CTC enrichment and immunostaining, improving on major challenges in circulating tumour cells CTC liquid biopsy testing, such as handling and standardization.
The ClearCell FX System is an automatic circulating tumour cells CTC enrichment system, powered by the patented CTChip FR1 microfluidics biochip. Using a label-free method, the ClearCell FX System retrieves wholly-intact and feasible CTCs from a standard blood draw. The gentle categorisation principle retains high cell integrity and cell surface antigen expression. This coupled with single-step CTC retrieval, provides a seamless integration into pathology lab workflows.
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312